New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 0.5mg - film coated tablet - 0.5 mg - active: riociguat 0.5mg excipient: crospovidone hyprolose hypromellose   lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 1.5mg - film coated tablet - 1.5 mg - active: riociguat 1.5mg excipient: crospovidone hyprolose hypromellose   iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 2.5mg - film coated tablet - 2.5 mg - active: riociguat 2.5mg excipient: crospovidone hyprolose hypromellose   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

Canada - English - Health Canada

bayer inc - riociguat - tablet - 0.5mg - riociguat 0.5mg - vasodilating agents

Canada - English - Health Canada

bayer inc - riociguat - tablet - 1.5mg - riociguat 1.5mg - vasodilating agents

Canada - English - Health Canada

bayer inc - riociguat - tablet - 2.5mg - riociguat 2.5mg - vasodilating agents

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - riociguat (unii: ru3fe2y4xi) (riociguat - unii:ru3fe2y4xi) - riociguat .5 mg - adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class [see clinical studies (14.1)]. adempas is indicated for the treatment of adults with pulmonary arterial hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening. efficacy was shown in patients on adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. studies establishing effectiveness included predominately patients with who functional class ii–iii and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (25%) [see clinical studies (14.2)] . based on data from animal reproduction studies, adempas may cause fetal harm when administered to a pregnant woman and is contraindicated in females who are pregnant. adempas was consistently

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

bayer ag - riociguat - riociguat....2.5 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

bayer ag - riociguat - riociguat....1.5mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

bayer ag - riociguat - riociguat....0.5mg